What is SolasCure?
Founded in 2017, SolasCure is a specialized biotechnology company dedicated to improving patient outcomes through advanced wound care products. The company's primary innovation, Aurase, is a hydrogel formulated with a highly specific enzyme derived from medical maggots. This unique approach to wound debridement is designed to facilitate faster cleaning and healing, thereby reducing the overall burden on healthcare systems.
SolasCure occupies a strategic position at the intersection of biotechnology and clinical care. By focusing on enzyme-based therapies, the company differentiates itself from traditional wound care providers. Its market position is bolstered by a robust research and development framework, which is essential for navigating the regulatory and clinical hurdles inherent in the pharmaceutical and medical device industries.
How much funding has SolasCure raised?
SolasCure has raised a total of $35.8M across 3 funding rounds:
Series A
$20.8M
Unspecified
$1.6M
Series B
$13.4M
Series A (2021): $20.8M with participation from Jonathan Milner, Eva Pharma, BRAIN Biotech AG, Development Bank of Wales, Bionova Capital, François Fournier, and Seneca Partners
Unspecified (2021): $1.6M led by Seneca Partners
Series B (2023): $13.4M supported by Wealth Club, Seneca Partners, Brain, and Eva Pharma
Key Investors in SolasCure
Seneca Partners
Seneca Partners is a specialist investment firm providing debt and equity solutions to SMEs, focusing on businesses that require capital to support their next phase of growth.
Eva Pharma
EVA Pharma is a leading pharmaceutical company with a century of expertise, focusing on innovating healthcare solutions across therapeutic areas like oncology and neuroscience.
BRAIN Biotech AG
BRAIN Biotech AG is a European supplier of biobased products and solutions, specializing in enzyme technology and microbial production for industrial and health applications.
What's next for SolasCure?
With the recent influx of capital, SolasCure is expected to prioritize the commercialization of its lead product, Aurase, while simultaneously expanding its research capabilities. The company's strategic roadmap likely includes scaling manufacturing processes to meet anticipated demand and conducting further clinical studies to validate the efficacy of its enzyme-based hydrogel across diverse patient populations.
Furthermore, the involvement of specialized biotech investors suggests a focus on long-term value creation through potential partnerships or licensing agreements. As SolasCure moves forward, the firm will likely leverage its existing intellectual property to explore additional applications for its enzyme technology, potentially diversifying its portfolio beyond current wound care offerings. The company remains a key entity to watch as it seeks to disrupt the standard of care in chronic wound management.
